Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) has provided a corporate update on its barium and iodine contrast media projects, highlighting advancements in feasibility studies, regulatory pathways, and strategic partnerships. The company aims to address critical supply chain vulnerabilities in the diagnostic imaging sector, which is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033. With barite classified as a critical mineral by the U.S. Geological Survey, Voyageur's strategy focuses on creating a secure, vertically integrated supply chain for both barium and iodine active pharmaceutical ingredients, covering the entire value chain from mineral discovery to finished product manufacturing.
The company is advancing two bankable feasibility studies (BFS): the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. The Frances Creek barium project, now in the BFS phase, hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical-grade barium sulfate, with recent testing confirming an average grade of 98.8% BaSO4, exceeding the 97.5% pharmaceutical grade threshold. Voyageur has completed product development for five Health Canada-approved barium products with Alberta Veterinary Laboratories and has generated approximately C$32,000 in initial contrast product sales, providing commercial validation. The company expects to deliver the FC barium BFS in the second half of 2026, following geotechnical drilling studies at the quarry site.
For iodine, Voyageur is independently advancing a prefeasibility study for iodine contrast media drug production, integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform. This project targets 35 million doses per year of iodine contrast drug production, leveraging iodine-rich brine from U.S. oil and gas operations. The company anticipates that combining these processes will significantly lower manufacturing costs. Additionally, the Bayer Iodine Project, supported by a US$2.35 million funding arrangement, focuses on completing a BFS. Subject to successful completion, Bayer and Voyageur may advance into a second phase under an offtake-linked production financing arrangement, where Bayer would provide capital financing and Voyageur would operate the project. All intellectual property developed would remain exclusively owned by Voyageur.
Regulatory pathways for barium and iodine contrast media are expected to follow an 18 to 24-month FDA review and approval process. Voyageur has commenced the FDA approval process for barium via the 505(b)(2) regulatory pathway, with the FDA expected to provide pending requirements in Q1 2026. The review process is anticipated to take approximately one year, with product testing projected at six to seven months. The company plans to advance a generic iodine FDA license in the second half of 2026. FDA approval would also enable registration of products in the European Union and other international markets.
Voyageur is engaging with a global engineering company to complete the final BFS for the radiology drug manufacturing project (combining FC barium and iodine drug prefeasibility) and the Bayer Iodine project. The company is targeting construction to commence in 2027, pending final feasibility studies and financing. Management believes these initiatives will position Voyageur as the only vertically integrated manufacturer of barium and iodine contrast media globally, from mineral extraction to finished product, ensuring affordable and secure supplies for healthcare authorities. The company's motto, "From Earth to Bottle," underscores its commitment to responsible sourcing and manufacturing. For more information, visit Voyageur Pharmaceuticals.
